Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy

J Surg Oncol. 2021 Jun;123(7):1513-1520. doi: 10.1002/jso.26438. Epub 2021 Mar 8.

Abstract

Background and objectives: The purpose of this study was to assess the utility of determining the biological features of synchronous axillary lymph node (syLN) metastasis of breast cancer in evaluating the efficacy of preoperative systemic chemotherapy (PST).

Materials and methods: The retrospective subjects initially comprised 59 patients (T1c-4 N1-3 M0) diagnosed with syLN metastasis via core needle biopsy who received PST. The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status in each patient was assessed in primary breast tumor (pBT) and syLNs using immunohistochemistry, and the patients were classified into HR(+), HER2(+), and triple negative breast cancer (TN) subtypes.

Results: Subtype shift (SS) of pBT in syLNs was observed in 28% cases for HR(+), in 6% cases for the HER2(+), and in 16% cases for the TN. The pCR rate of the pBT and syLNs types were 45% and 36% in the HR(+), 45% and 39% in the TN, and 94% and 100% in the HER2(+), respectively. In SS cases, the pCR rate was significantly higher in 75% cases compared with 33% of the no-SS cases.

Conclusion: A SS in syLNs was more frequent in HR(+) than in other types.

Keywords: axillary lymph node metastases; biology; breast cancer; preoperative systemic chemotherapy; synchronous.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy, Large-Core Needle
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Cyclophosphamide / administration & dosage
  • Docetaxel / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Preoperative Care / methods
  • Retrospective Studies

Substances

  • Docetaxel
  • Doxorubicin
  • Cyclophosphamide